Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews research on dietary supplements. It is informational only and is not medical advice. Not medical advice. Consult a qualified healthcare professional before starting any supplement regimen, especially if you take prescription medications, have a chronic health condition, or are pregnant or breastfeeding.

The decision most beginners face

Most readers arrive at longevity supplementation with a version of the same question: I keep seeing NMN, CoQ10, omega-3s, and astaxanthin mentioned together in Japanese longevity contexts. Which ones have real evidence? Where do I start?

That question has a reasonably honest answer, because these five supplements — NMN or NR, CoQ10, magnesium, fish-derived omega-3, and astaxanthin — are not randomly grouped. Each has a distinct Japan-linked evidence thread, a meaningful (if uneven) human research base, and an identifiable rationale for a beginning stack. What they do not have, with one partial exception, is confirmed clinical-outcome data in healthy adults.

This article covers what each supplement is for, what the evidence actually shows, what Japan’s role is in each category, dose ranges used in trials, and where to buy at a reasonable quality level.

TL;DR

• NMN / NR: reliably raises blood NAD+; human clinical outcome data (reduced disease, mortality) does not yet exist. Japan is the world’s leading NMN production market. 250–500 mg/day is the trial-supported dose range.
• CoQ10: the Q-SYMBIO trial produced real cardiovascular event data in severe heart failure patients at 300 mg/day. Kaneka Corporation (Japan) is the world’s primary CoQ10 ingredient supplier. Not a proven benefit in healthy adults.
• Magnesium: the most likely real deficiency gap among these five. National dietary surveys find roughly 45–50% of US adults consuming below the RDA. Associated with blood pressure and metabolic markers in epidemiological data.
• Fish-derived omega-3: JPHC cohort data links 60+ g/day dietary fish consumption to approximately 40% lower fatal coronary event risk. Supplement RCTs show reliable triglyceride lowering; hard cardiovascular outcome data is mixed.
• Astaxanthin: smallest evidence base of the five; preliminary data on skin photoprotection and lipid oxidation markers. Japan developed the commercial microalgae production process.

NMN / NR: NAD+ precursors with Japan ties

Both nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are converted by the body into NAD+, a coenzyme involved in energy metabolism, DNA repair via PARP enzymes, and sirtuin activity. NAD+ declines with age across essentially every species studied. The supplement thesis is that restoring NAD+ levels in older adults may support some cellular processes that decline with aging.

What the evidence shows: Human trials published 2021–2025 have consistently found that both compounds raise blood NAD+ at studied doses. Yoshino et al. 2021 (25 postmenopausal women with prediabetes, 250 mg/day NMN for 10 weeks) showed improved muscle insulin sensitivity. Igarashi et al. 2022 found modest improvements in walking speed and grip strength at 250 mg/day in older adults. Liao et al. 2023 used doses of 300, 600, and 900 mg/day over 60 days; NAD+ rose dose-dependently, subjective wellness measures improved, and objective performance changes were small. Neither compound has produced a clinical outcome result (reduced disease incidence, mortality) in human trials as of 2026.

Dose range from trials: 250–500 mg/day for either compound. The dose-response curve for NAD+ raising flattens above roughly 500–600 mg/day; higher doses are a marketing argument rather than a trial-supported one.

Japan angle: Keio University produced several of the foundational NMN human trials (Yoshino et al. and Igarashi et al. were Keio collaborations). Japan has pharmaceutical-scale NMN producers — Mitsubishi and Shinkoso — whose purity documentation is typically more rigorous than the fragmented US NMN market.

Regulatory note: NR has clean FDA dietary-supplement status (ChromaDex’s Tru Niagen). NMN’s US status has been contested since the FDA’s 2022 reclassification; sales continue but with unresolved regulatory ambiguity.

Side effects: At studied doses over 4–24 weeks, both compounds show clean tolerability relative to placebo. Occasional digestive discomfort, mild flushing, and sleep disturbance at higher doses have been reported. Long-term safety beyond 24 months is preliminary for both compounds.

For US buyers: iHerb carries NMN from multiple brands, including Japanese-source options. ChromaDex’s Tru Niagen (NR) is available through major retailers. Third-party certificates of analysis matter in both categories.

CoQ10 / Ubiquinol: mitochondrial support with the clearest RCT anchor

Coenzyme Q10 is a fat-soluble compound in the mitochondrial inner membrane, central to the electron transport chain that produces ATP. It also functions as a fat-soluble antioxidant. Tissue CoQ10 declines with age; research published in BioFactors (2006) estimated a 40–50% decline in cardiac CoQ10 content between the third and eighth decade of life from human postmortem tissue samples.

What the evidence shows: The strongest clinical data is Q-SYMBIO (Mortensen et al., JACC Heart Failure, 2014, PubMed 25282089): 420 patients with severe chronic heart failure (NYHA class III–IV) randomized to CoQ10 (ubiquinone) 300 mg/day or placebo for 2 years. The primary composite cardiovascular endpoint occurred in 15% of the CoQ10 group versus 26% of the placebo group; cardiovascular mortality was 9% versus 16%. These are statistically significant absolute differences in a high-event-rate population.

The critical limitation: Q-SYMBIO was a single trial in severe heart failure patients already on optimal background cardiac therapy. It has not been replicated in a second independent trial with the same design, and its findings do not directly inform the decision of a healthy adult taking CoQ10 as a general wellness supplement.

Ubiquinone vs. ubiquinol: Hosoe et al. 2007 (Regulatory Toxicology and Pharmacology, PubMed 17543416) found that at 150–300 mg/day, ubiquinol produces approximately 1.5–2× higher plasma CoQ10 than ubiquinone. Below 100 mg/day the two forms are broadly comparable. Q-SYMBIO used ubiquinone at 300 mg/day; the absorption advantage of ubiquinol at that dose has not been directly tested in a cardiac-outcome trial.

Japan angle: Kaneka Corporation (Osaka) is the world’s primary CoQ10 ingredient manufacturer. When US supplement brands print “Kaneka QH” on a ubiquinol label, they are using Japanese-produced raw material. The commercial CoQ10 market was developed in Japan.

Dose: 100–200 mg/day ubiquinol with a fat-containing meal for general use. CoQ10 is fat-soluble; fasted absorption is substantially lower for both forms.

Interactions: Warfarin users should discuss CoQ10 with their prescriber before starting — CoQ10 is structurally related to vitamin K and can reduce anticoagulant effect. Statin users have a separate rationale: statins deplete endogenous CoQ10 via HMG-CoA reductase inhibition; the clinical significance is debated, but the depletion relationship is real.

iHerb carries Doctor’s Best CoQ10 (ubiquinone) and Jarrow Formulas QH-Absorb (ubiquinol) with third-party testing documentation.

Magnesium: the most common real deficiency in this stack

Magnesium is an essential mineral involved in more than 300 enzymatic reactions, including ATP synthesis, protein synthesis, nerve function, and muscle contraction. Unlike the other four supplements here, the primary rationale for including magnesium is not longevity-specific research but baseline deficiency: national dietary surveys, including multiple NHANES cycles, have found that roughly 45–50% of US adults consume below the RDA (310–420 mg elemental magnesium/day depending on age and sex).

What the evidence shows: Multiple large cohort studies have associated adequate dietary magnesium intake with lower incidence of type 2 diabetes and cardiovascular events — the mechanistic pathway runs through insulin signaling and vascular smooth muscle function. A 2016 meta-analysis of 34 randomized trials (Zhang X et al., Hypertension, 2016) found supplemental magnesium associated with a mean reduction of 4.18 mmHg systolic and 2.27 mmHg diastolic blood pressure, primarily in hypertensive adults. These are epidemiological associations; magnesium supplementation has not produced confirmed mortality benefit in a clinical-endpoint trial.

Form matters: Magnesium oxide absorbs poorly (some assessments put bioavailability below 5%). Glycinate and citrate forms absorb substantially better. Magnesium L-threonate appears to cross the blood-brain barrier more readily and is used in sleep and cognitive function trials, though at higher cost per milligram of elemental magnesium.

Dose for supplementation: 100–300 mg elemental magnesium/day from a well-absorbed form is the range used in most dietary-gap-filling contexts. Check the label for elemental magnesium content rather than total compound weight; a 500 mg magnesium glycinate capsule contains roughly 60–70 mg elemental.

Japan angle: High magnesium content in mineral-rich mountain water is an observed dietary characteristic of some Japanese longevity regions. This is a correlation observed in regional dietary surveys — not an established causal pathway — but it is a consistent feature of Japanese longevity community diets.

Side effects: Excess supplemental magnesium causes loose stools, particularly with oxide and citrate forms. Adults with chronic kidney disease may not excrete magnesium normally; supplementation in this group warrants physician guidance.

Fish-derived omega-3 (EPA/DHA): closest to an established dietary pattern

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are long-chain omega-3 fatty acids concentrated in fatty fish. The supplement form is an extraction of the same compounds found in the fish-heavy Japanese dietary pattern that underlies much of the cohort-based longevity evidence from Japan.

What the evidence shows: The JPHC cohort (a large Japanese prospective study tracked from the early 1990s) found that dietary fish consumption of 60+ g/day was associated with approximately 40% lower fatal coronary event risk compared to low-consumption groups. This is dietary pattern data in a specific population, not supplementation data. Supplement RCTs have shown reliable reduction in plasma triglycerides at 2–4 g/day combined EPA/DHA. Cardiovascular hard-outcome data from supplement trials is more mixed: REDUCE-IT (high-dose icosapentaenoic acid at 4 g/day in a statin-treated high-cardiovascular-risk population) showed event reduction; STRENGTH and ASCEND used different formulations and populations, with smaller or null effects.

Dose range from trials: 1–2 g combined EPA/DHA per day for general cardiovascular support. Triglyceride-lowering applications use 2–4 g/day.

Japan angle: The JPHC cohort data is the clearest Japan-linked longevity evidence thread for omega-3, and it is on dietary fish, not capsules. Supplement omega-3 approximates part of that pattern but is not a functional equivalent of a dietary pattern that also includes the protein, other micronutrients, and dietary context of regular fish consumption.

Sourcing note: Oxidized fish oil produces off-flavors and may be counterproductive at high doses. Fresh smell, a manufacture date within 12 months, and nitrogen-flushed packaging are the practical quality signals. iHerb and Amazon both carry Nordic Naturals and Carlson Labs options that have established quality documentation.

Side effects: Fishy burps (take with food or use enteric-coated capsules). At 3+ g/day, blood thinning effects are possible — relevant if you also take anticoagulants or other blood-thinning supplements such as nattokinase.

Astaxanthin: the smallest evidence base of the five

Astaxanthin is a carotenoid xanthophyll synthesized by Haematococcus pluvialis microalgae and concentrated up the food chain in krill, salmon, and shrimp. It is a lipophilic antioxidant that incorporates into cell membranes and has been studied primarily for skin photoprotection and lipid oxidation markers.

What the evidence shows: Small RCTs have found astaxanthin associated with reduced skin aging markers at 4–12 mg/day — specifically UV-induced skin damage, skin elasticity loss, and fine lines in trials of 8–16 weeks in middle-aged adults. Some lipid trials have found modest improvements in LDL oxidation markers. The evidence base here is the smallest and least consistent of the five supplements in this stack. The antioxidant mechanism is biologically plausible; clinical significance in healthy adult populations remains preliminary.

Dose range: 4–12 mg/day. Absorption is fat-dependent; take with a fat-containing meal.

Japan angle: Japan developed the commercial production of astaxanthin from Haematococcus microalgae in the 1990s, shifting from byproduct extraction (salmon, shrimp processing) to controlled microalgae cultivation. AstaReal (a subsidiary of Fuji Chemical Industry, a Japanese company) is the most heavily cited astaxanthin supplier in the peer-reviewed literature and is available on iHerb and Amazon.

Side effects: Well-tolerated at studied doses. High doses (> 20 mg/day for extended periods) may produce mild skin yellowing from carotenoid accumulation. No serious adverse events at commercial doses in published trials.

Building the stack incrementally

A beginner assembling this stack for the first time should sequence by where the evidence-to-deficiency gap is widest, not by what is most marketed.

Start with magnesium if your diet is not consistently high in whole grains, legumes, nuts, and leafy greens. The deficiency gap is the widest of these five, the epidemiological evidence is the most broadly applicable, and the cost is lowest. 150–200 mg elemental magnesium (glycinate or citrate) with dinner for 4–6 weeks.

Add omega-3 next if dietary fish consumption is below 2–3 servings per week. This supplement most directly approximates an established dietary pattern associated with the cohort data. 1–2 g combined EPA/DHA with the fattiest meal of the day.

Add CoQ10 if you are on a statin, are over 45 and want to address the age-related CoQ10 decline, or have any cardiac history (the last case warrants physician discussion). 100–200 mg ubiquinol with a fat-containing meal.

Add astaxanthin if skin photoprotection or lipid oxidation is the specific concern. 6–12 mg with a fat-containing meal. This is the most specialized entry of the five for most beginners.

Add NMN or NR last, once the above are stable. If you want exposure to the NAD+ thesis with the understanding that human outcome evidence remains preliminary, 250–500 mg/day of either compound is the trial-supported range. Choose NR for cleaner US regulatory status; choose NMN for the broader Japanese pharmaceutical-grade market.

Adding one supplement at a time with a 4–6 week stabilization window between additions allows you to notice what changes and, if anything goes wrong, identify which compound is responsible.

Who should not start this stack without physician guidance

• Anyone on warfarin or other anticoagulant therapy (CoQ10 and high-dose omega-3 both have relevant interaction profiles)
• Anyone currently in active cancer treatment — NAD+ pathway supplements have unresolved theoretical considerations in oncological contexts; discuss NMN and NR with your oncologist before starting
• Adults with chronic kidney disease (impaired magnesium excretion; also iodine considerations with some omega-3 products)
• Pregnant or breastfeeding women (limited or absent safety data for most of these at supplemental doses)
• Anyone within several weeks of surgery (CoQ10 and omega-3 may affect bleeding)

For healthy adults outside these risk factors, this stack represents one of the better-evidence-supported starting points in the longevity supplement space — not because any of the five is confirmed to extend healthy lifespan, but because each has a specific Japan-linked evidence thread, a coherent mechanism, and a relatively clean safety profile at studied doses.

Revisit the stack annually. The NMN and NR evidence base in particular is moving; several mid-sized clinical-endpoint trials are expected 2026–2028 that will substantially clarify whether the NAD+ thesis holds in healthy adults. What is preliminary now will not be preliminary indefinitely.

---

See also: NMN vs NR: what human trials actually compare on dose, cost, and safety, CoQ10 vs Ubiquinol: what cardiac RCTs and absorption data actually show, iHerb Japanese supplement guide.